3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
2
Completed
2
Active not recruiting
2
Recruiting
1
Sponsor Class
OTHER
3
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Neoplasms
1905
Breast Neoplasms
1425
Carcinoma, Non-Small-Cell Lung
1178
Prostatic Neoplasms
740
Colorectal Neoplasms
686
Neoplasm Metastasis
623
Multiple Myeloma
548
Melanoma
529
Ovarian Neoplasms
456
Lung Neoplasms
447
Lymphoma, Non-Hodgkin
385
Lymphoma
374
Recurrence
373
Leukemia, Myeloid, Acute
370
Pancreatic Neoplasms
358
Carcinoma, Renal Cell
339
Carcinoma, Hepatocellular
286
Stomach Neoplasms
281
Leukemia, Lymphocytic, Chronic, B-Cell
268
Lymphoma, Follicular
254
Head and Neck Neoplasms
246
Glioblastoma
220
Leukemia
215
Small Cell Lung Carcinoma
183
Lymphoma, Large B-Cell, Diffuse
183
Squamous Cell Carcinoma of Head and Neck
181
Urinary Bladder Neoplasms
175
Carcinoma
175
Uterine Cervical Neoplasms
174
Advanced Solid Tumors
161
Interventions
pembrolizumab
2
vicriviroc
1
binimetinib
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
INDUSTRY
×
Spinocerebellar Degenerations
×
Clear all
NCT03374254
2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1
Completed
116 enrolled
18 charts
NCT03631407
2024-11-21
MK-7690-046
Merck Sharp & Dohme LLC
Phase 2
Completed
41 enrolled
20 charts